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Abstract
Background: Early age at menarche, nulliparity, late age at first completed pregnancy, and never having breastfed,
are established breast cancer risk factors. However, among breast cancer subtypes, it remains unclear whether all of
these are risk factors for triple-negative breast cancer (TNBC).
Methods: We evaluated the associations of these reproductive factors with TNBC, in 2658 patients with breast
cancer (including 554 with TNBC) and 2448 controls aged 20–64 years, who participated in one of the three
population-based case-control studies: the Women’s Contraceptive and Reproductive Experiences Study, the
Women’s Breast Carcinoma in situ Study, or the Women’s Learning the Influence of Family and Environment Study.
We used multivariable polychotomous unconditional logistic regression methods to conduct case-control
comparisons among breast cancer subtypes defined by estrogen receptor, progesterone receptor, and human
epidermal growth factor receptor-2 expression status.
Results: TNBC risk decreased with increasing duration of breastfeeding (Ptrend = 0.006), but age at menarche, age at
first completed pregnancy, and nulliparity were not associated with risk of TNBC. Parous women who breastfed for
at least one year had a 31% lower risk of TNBC than parous women who had never breastfed (odds ratio, OR = 0.69;
95% confidence interval, CI = 0.50–0.96). The association between breastfeeding and risk of TNBC was modified by age
and race. Parous African-American women aged 20–44 years who breastfed for 6 months or longer had an 82% lower
risk of TNBC than their counterparts who had never breastfed (OR = 0.18, 95% CI = 0.07–0.46).
Conclusions: Our data indicate that breastfeeding decreases the risk of TNBC, especially for younger African-American
women.
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Background
Breast cancer occurs more frequently than any other type
of cancer in women worldwide, with an estimated 1.4 mil-
lion new cases annually [1]. Based on immunohistochemi-
cal analyses of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor
receptor-2 (HER2), breast cancer has been classified into
luminal A-like (ER-positive (ER+) and/or PR-positive
(PR+), HER2-negative (HER2–)), luminal B-like (ER+
and/or PR+, HER2-positive (HER2+)), HER2-enriched
(ER-negative (ER–)/PR-negative (PR–)/HER2+), and triple-
negative breast cancer (TNBC; ER–/PR–/HER2–) [2–10].
The luminal A-like subtype is the most frequent sub-
type and accounts for 62–67% of invasive cases; TNBC
is the second most common subtype and accounts for
10–25% of invasive cases [11, 12]. Compared with the
luminal A-like subtype, TNBC is disproportionately
more common in younger or premenopausal women, es-
pecially young African-American women [13–16].
TNBC is biologically more aggressive and has poorer
prognosis than the luminal A-like subtype [7, 12, 17].
Moreover, unlike ER+ or HER2+ breast cancer, for
which there are targeted therapies, including anti-
estrogen and monocolonal antibody therapies, there are
no targeted therapies for TNBC [12, 18]. Therefore, cur-
rently the only treatment option for TNBC is systemic
chemotherapy [12, 18]. The overall 5-year survival rate
in patients with TNBC is at least 10% lower than in
women with the luminal A-like subtype [19]. These
TNBC characteristics underscore the need to identify spe-
cific TNBC risk factors, which could provide critical clues
for TNBC prevention strategies. However, the impact of
established breast cancer risk factors, such as reproductive
factors, on the risk of TNBC remains inconclusive,
possibly because too few patients with TNBC have been
included in the majority of published studies [6, 10, 15,
20–32]. Moreover, little is known about the impact of race
and age on reproductive risk of TNBC.
Here, we evaluated the associations between TNBC
and age at menarche, number of completed (longer than
26-week gestation) pregnancies, age at first completed
pregnancy, and breastfeeding in an analysis pooling data
from three case-control studies. We compared the risk
estimates for TNBC with other ER/PR/HER2-defined
specific subtypes, especially luminal A-like breast cancer.
We also explored whether the associations between
these factors and risk of TNBC differ by race (white,
African-American) and age (<45, ≥45 years). Among our
three source studies, one has published data on reproduct-
ive factors (including number of completed pregnancies,
age at first completed pregnancy, and breastfeeding) and
the risk of breast cancer by ER/PR/HER2 status [6]. An-
other has published data on hormone-related risk factors
for breast cancer by ER/PR status [33] and has also
published characteristics of TNBC in patients with and
without a BRCA1 mutation [34]. No data on breast cancer
risk according to the expression of ER, PR, or HER2 have
been published from the third study [35].
Methods
Study population and data collection
Eligible participants for this analysis were women who had
previously participated in one of the three population-
based case-control studies - the Women’s Contraceptive
and Reproductive Experiences (CARE) Study [6], the
Women’s Breast Carcinoma in situ (BCIS) Study [35],
or the Women’s Learning the Influence of Family and
Environment (LIFE) Study [33].
The Women’s CARE Study, which was supported by
National Institute of Child Health and Human Develop-
ment (NICHD), was a population-based, case-control
study designed to examine risk factors for invasive breast
cancer among USA-born white women and African-
American women [36]. The age distribution and partici-
pant response rates by study site, case-control status,
and race have been published [36]. The Women’s CARE
Study selected a stratified (by age group) random sample
of women aged 35–64 years who were newly diagnosed
with histologically confirmed incident invasive breast
cancer (International Classification of Diseases for On-
cology (ICD-O) codes: C50.0–C50.9) between July 1994
and April 1998. African-American women were over-
sampled to maximize their numbers in the study, and
white women were sampled to provide approximately
equal numbers of women in each 5-year age category
(from 35 to 64 years).
Control participants were women with no history of
invasive or in situ breast cancer who were identified by
random digit dialing from August 1994 through Decem-
ber 1998 and were frequency-matched to the expected
distribution of patients with breast cancer in strata defined
by 5-year age groups, race (white or African-American)
and geographic region of residence [6]. The participants
in the Women’s CARE Study involved in the analyses
presented here are women from Los Angeles (LA) and
Detroit, the two sites where tumor tissue samples were
collected. Tissue collection, as part of the Women’s CARE
Study, was supported by NICHD, as advised by the
Women’s CARE Study Steering Committee [36]. The
Women’s CARE Study recruited 1921 case participants
(1072 white and 849 African-American women) and 2034
control participants (1161 white and 873 African-
American women) from LA and Detroit. Of 1921 case
participants, 1206 had ER/PR/HER2 status assessed in a
centralized pathology laboratory at University of Southern
California (USC).
The Women’s BCIS Study investigated risk factors for
BCIS among USA-born white women and African-
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American women who resided in LA County [35]. Case
participants were USA-born and English-speaking white
women and African-American women ages 35–64 years,
who were newly diagnosed with a first primary BCIS
(ICD-O codes: C50.0–C50.9) between March 1995 and
April 1998 (n = 567). The questionnaire developed for
the Women’s CARE Study was used to interview women
with BCIS, and both studies were conducted during the
same time period by the same interviewers and with ER,
PR and HER2 status determined in the same central la-
boratory using the same classifications (see subsequent
text). No additional controls were recruited for the BCIS
Study. LA control participants from the Women’s CARE
Study were deemed eligible to be controls for the BCIS
Study. For the analysis presented here, we excluded 37
case participants with lobular carcinoma in situ (LCIS,
ICD-O morphology code: 8520) because LCIS is not in-
cluded in the clinical definitions of in situ breast cancer
[37]; thus, 530 case participants remained. ER/PR/HER2
status was assessed in 343 of these case participants, at a
centralized pathology laboratory at USC.
The Women’s LIFE Study investigated genetic and epi-
demiologic risk factors for invasive breast cancer in
USA-born white women and African-American women
who resided in LA County [33, 38]. Case participants
were women aged 20–49 years who were diagnosed with
a first primary invasive breast cancer (ICD-O codes:
C50.0–C50.9) between February 1998 and May 2003 and
who resided in LA county (n = 1794). Of 1794 case par-
ticipants, 1167 had ER/PR/HER2 status abstracted from
pathology reports. Control participants were women
ages 20–49 years who had no history of invasive or in
situ breast cancer. Recruitment of control participants
did not begin until 1 July 2000. Control participants
were individually matched by race (white and African-
American), age (within 5 years and ages 20–49 years),
and neighborhood to the subset of case participants who
were diagnosed between 1 July 2000 and 31 May 2003
(n = 444). The Women’s LIFE Study used an expanded
version of the Women’s CARE Study questionnaire,
which was modified to include additional risk factors
(e.g., medical radiation exposure).
For all three studies, detailed information prior to the
reference date on reproductive factors and covariates in-
volved in this analysis was collected by trained staff who
administered standardized, in-person interviews using
structured questionnaires. The reference date for a case
participant was the date of breast cancer diagnosis; the
reference date for a control participant was the date on
which she was identified by random digit dialing in the
Women’s CARE Study, or the date of initial contact in
the Women’s LIFE Study.
After pooling the data from three source studies, 2716
case participants with data on receptors and 2478 control
participants were potentially eligible. We excluded 58 case
participants and 30 control participants for whom informa-
tion was missing on age at menarche (4 cases, 1 control),
parity (4 cases, 6 controls), duration of oral contraceptive
use (16 cases, 5 controls), education (9 cases, 1 control),
body mass index (BMI, 15 cases, 12 controls), recreational
physical activity (5 cases, 3 controls), smoking status (2
cases), and alcohol intake (3 cases, 2 controls). This resulted
in 2658 case participants (the Women’s CARE Study: 1197,
the Women’s BCIS Study: 342, the Women’s LIFE Study:
1119) and 2448 control participants (the Women’s CARE
Study or the Women’s BCIS Study: 2011, the Women’s
LIFE Study: 437) available for the current pooled analysis.
Assessment of biomarkers
The ER/PR/HER2 status in breast tumors in the Women’s
CARE Study and the Women’s BCIS Study was determined
in a centralized pathology laboratory at USC using immu-
nohistochemistry (IHC) methods [39, 40]. For ER and PR,
at least 100 tumor cells were examined from each specimen
and immunostaining of tumor cell nuclei ≥1% was consid-
ered positive [41]. HER2 expression was determined by
IHC using the 10H8 monoclonal antibody [42, 43]. No (0)
or weak (1+) membrane immunostaining was considered
HER2–. Moderate (2+) or strong membrane immunostain-
ing (3+) was considered HER2+, based on previous valid-
ation results from the same pathology laboratory [42]. In
the Women’s LIFE Study, the information on ER/PR/HER2
status was abstracted from pathology reports collected
through the Los Angeles Cancer Surveillance Program
(LACSP), a member of the population-based California
Cancer Registry and also sponsored by the National Cancer
Institute’s SEER program [34].
The ER/PR/HER2 status abstracted from pathology re-
ports for case participants in the Women's LIFE Study
was assessed by many pathology laboratories. These la-
boratories might have used different methods or differ-
ent cut-off points for positive receptor status, which
could cause concerns about consistency with the bio-
marker data from the centralized pathology laboratory at
USC. We previously validated the SEER registry ER/PR
status data for 1048 Women’s CARE case participants in
the centralized pathology laboratory at USC, which
showed that the agreement between the centralized la-
boratory and SEER registry classification was substantial
for both ER/PR (κ statistics: 0.70 and 0.60 for ER and
PR, respectively), and that the associations between risk
of ER/PR breast cancer subtypes and parity, age at first
completed pregnancy, and breastfeeding were similar re-
gardless of the source of information on ER/PR [44].
Statistical analyses
We assessed the associations between TNBC (ER-/PR-/
HER2-) or the other three subtypes of breast cancer
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defined by ER/PR/HER2 status (luminal A-like, ER+
and/or PR+ plus HER2–; luminal B-like, ER+ and/or PR+
plus HER2+; and HER2-enriched, ER–/PR–/HER2+), and
the following factors: age at menarche, number of com-
pleted (longer than 26-week gestation) pregnancies, age at
first completed pregnancy (defined for each woman as the
age at which that pregnancy ended), and duration of
breastfeeding. We estimated odd ratios (ORs) and corre-
sponding 95% confidence intervals (95% CIs) using multi-
variable polychotomous unconditional logistic regression
for case-control comparisons [45].
Tests for trend were conducted by fitting ordinal
values corresponding to exposure categories and testing
whether the slope coefficient differed from zero. We also
conducted Wald chi-square tests for homogeneity of the
associations with reproductive factors across breast can-
cer subtypes by fitting a multivariable polychotomous
unconditional logistic regression model for dichotomous
or ordinal variables.
We included the following factors, selected a priori, as
potential confounders in all multivariable models: source
study (the Women’s CARE Study or the Women’s BCIS
Study, the Women’s LIFE Study), study site (LA, Detroit),
race (white, African-American), education as a proxy for
socioeconomic status (high school or lower level of educa-
tion, technical school or some college education, college
graduate), age (<40, 40–44, 45–49, 50–54, 55–59, 60–64
years), family history of breast cancer (first-degree
(mother, sister, or daughter), no first-degree family his-
tory), BMI (<25, 25–29, ≥30 kg/m2), a variable combining
menopausal status and hormone therapy use (premeno-
pausal; postmenopausal: never used hormone therapy,
ever used hormone therapy; unknown menopausal status),
lifetime recreational physical activity (inactive, ≤2.2, 2.3–
6.6, 6.7–15.1, ≥15.2 annual metabolic equivalents of
energy expenditure (MET) hours/week), alcohol intake
(never, former, current), cigarette smoking status
(never, former, current), and oral contraceptive use
(never, <1, 1–4, 5–9, ≥10 years).
We also included age at menarche (≤12, 13, ≥14)
and number of completed pregnancies (never preg-
nant, 1, 2, ≥3, only non-completed pregnancy) as potential
confounders when they were not the exposure of interest.
When parity was the exposure of interest, we chose
women who had never been pregnant as our reference
group and treated women who had been pregnant but had
never carried to completed pregnancy as a separate group
that was excluded when testing for trend across categories
of parity. Only parous women were included in analyses of
age at first completed pregnancy and breastfeeding. Models
for parous women were also mutually adjusted for number
of completed pregnancies (1, 2, ≥3), age at first completed
pregnancy (≤20, 21–24, 25–29, ≥30 years), and duration of
breastfeeding (never, <6, 6–11, ≥12 months).
Using two major subtypes - TNBC and luminal A-like
breast cancer, we explored whether any associations of
reproductive factors differed by race (white women or
African-American women) or age group (younger
(<45 years) or older (≥45 years) women). In stratified
analyses by age, the variable for combining menopausal
status and hormone therapy use was only included in the
models for older women. When testing the effect of
breastfeeding by both race and age, we combined two cat-
egories (6–11, ≥12 months) of longer duration of breast-
feeding into one (≥6 months) to avoid having groups with
small numbers of study participants after stratification.
As the commonly used definition (ER+ and/or PR+
plus HER2–) of the luminal A-like subtype probably in-
cludes both luminal B-like and luminal A-like tumors,
we also used the 13th St. Gallen International Breast
Cancer Conference (2013) Expert Panel recommenda-
tion to define ER+/PR+/HER2– as the luminal A-like
subtype [46], and repeated our analysis by the following
five subtypes: luminal A-like (ER+/PR+/HER2–), luminal
B-like-HER2– (ER+ or PR+ plus HER2–), luminal B-like-
HER2+ (ER+ and/or PR+ plus HER2+), HER2-enriched
(ER–/PR–/HER2+), and TNBC (ER–/PR–/HER2–). It is
noteworthy that the St. Gallen Panel recommendation re-
quires information on Ki-67 and percentage of PR in PR+
tumors; however, we lacked data on Ki-67 in all source
studies and did not have quantitative data for PR in the
Women’s LIFE Study. Moreover, in order to exclude the
possibility that ORs for some reproductive factors associ-
ated with in situ breast cancer are different from those as-
sociated with the results presented here, we repeated our
analyses after excluding all in situ breast cancer cases.
In reporting the results of trend tests or homogeneity
tests, we considered a two-sided P value <0.05 as statisti-
cally significant. All analyses were performed using the
SAS statistical package (Version 9.3, SAS Institute, Cary,
NC, USA).
Results
Characteristics of case participants and controls
The subtypes of breast cancer in the 2658 case partici-
pants were distributed as: TNBC (n = 554, 20.8%), lu-
minal A-like (n = 1517, 57.1%), luminal B-like (n = 360,
13.5%), and HER2-enriched (n = 227, 8.5%) (Table 1).
The 2448 control participants comprised 1549 white
women and 899 African-American women. Overall,
mean age at menarche in control participants was
12.4 years; 81.3% of control participants had at least one
completed pregnancy. Among control participants, the
mean number of completed pregnancies was 2.7 in par-
ous women, and their mean age at first completed preg-
nancy was 23.2 years. Among parous control
participants who had ever breastfed (62.4%), the mean
duration of breastfeeding was 12.1 months.
Ma et al. Breast Cancer Research  (2017) 19:6 Page 4 of 14
Reproductive factors and risk of four ER/PR/HER2-defined
subtypes
Age at menarche was not associated with TNBC
(Ptrend = 0.55; Table 2), luminal B-like (Ptrend = 0.70), or
HER2-enriched (Ptrend = 0.56) breast cancer, but was asso-
ciated with luminal A-like subtype (Ptrend = 0.009).
Women whose menarche occurred at age 14 years or later
had a 23% lower risk of luminal A-like breast cancer (OR
= 0.77, 95% CI = 0.64–0.92) than women whose menarche
occurred at age 12 years or earlier. Number of completed
pregnancies was not associated with the risk of TNBC
(Ptrend = 0.26), but was inversely associated with the risk of
the other three subtypes (all Ptrend ≤0.02).
Among parous women, older age at first completed
pregnancy was not associated with any ER/PR/HER2-de-
fined specific subtypes, except for the luminal A-like
subtype (Ptrend = 0.05). There was a statistically signifi-
cant inverse association between longer duration of
breastfeeding and TNBC (Ptrend = 0.006) and luminal A-
like cancer (Ptrend = 0.004), but no association with the
other two subtypes of breast cancer (both Ptrend ≥0.28).
None of the differences in trends across the four sub-
types of breast cancer was statistically significant for age at
menarche (P for homogeneity of trends = 0.19), parity (P
for homogeneity of trends = 0.09), age at first completed
pregnancy (P for homogeneity of trends = 0.24), or duration
of breastfeeding (P for homogeneity of trends = 0.08).
Reproductive factors and risk of TNBC and luminal A-like
subtype by race
Among either white women or African-American
women, risk of TNBC was not associated with age at
menarche number of completed pregnancies, or age at
first completed pregnancy (Table 3). However, among
white women, risk of luminal A-like breast cancer was
inversely associated with age at menarche (Ptrend = 0.02)
and number of completed pregnancies (Ptrend = 0.0005).
Longer duration of breastfeeding was modestly associ-
ated with a lower risk of TNBC in parous African-
American women and a lower risk of the luminal A-like
subtype in both parous white women and parous African-
American women; however, statistically significant dose-
Table 1 Characteristics of breast cancer case participants and control participants
Overall By study
Women’s CARE Women’s BCIS Women’s LIFE
Case participants N = 2658 N = 1197 N = 342 N = 1119
Mean age at diagnosis, years (SD, range) 46.7 (8.1, 22-64) 49.0 (8.6, 35-64) 51.8 (7.3, 35-64) 42.7 (5.4, 22-49)
Race
White 1960 (73.7%) 678 (56.6%) 287 (83.9%) 995 (88.9%)
African-American 698 (26.3%) 519 (43.4%) 55 (16.1%) 124 (11.1%)
Subtype of breast cancer
Triple-negative 554 (20.8%) 335 (28.0%) 21 (6.1%) 198 (17.7%)
Luminal A-like 1517 (57.1%) 645 (53.9%) 233 (68.1%) 639 (57.1%)
Luminal B-like 360 (13.5%) 121 (10.1%) 49 (14.3%) 190 (17.0%)
HER2-enriched 227 (8.5%) 96 (8.0%) 39 (11.4%) 92 (8.2%)
Control participants N = 2448 N = 2011a ─ N = 437
Mean age at reference date, years (SD, range) 47.8 (8.3, 24-64) 48.9 (8.4, 35-64) ─ 42.6 (4.9, 24-49)
Race
White 1549 (63.3%) 1147 (57.0%) ─ 402 (92.0%)
African-American 899 (36.7%) 864 (43.0%) ─ 35 (8.0%)
Mean age at menarche, years (SD) 12.4 (1.6) 12.4 (1.6) ─ 12.7 (1.5)
Ever had a completed (>26-week) pregnancy 1990 (81.3%) 1677 (83.4%) ─ 313 (71.6%)
Among parous women N = 1990 N = 1677 N = 313
Mean number of completed pregnancies (SD) 2.7 (1.5) 2.8 (1.6) ─ 2.2 (1.1)
Mean age at first completed pregnancy (SD) 23.2 (5.7) 22.5 (5.3) ─ 27.1 (6.2)
Ever breastfed 1242 (62.4%) 967 (57.7%) ─ 275 (87.9%)
Mean duration of breastfeeding among those who breastfed, months (SD) 12.1 (15.0) 10.9 (14.4) ─ 16.2 (16.5)
aIncluding those who also served as controls in the Women’s BCIS. Triple-negative = estrogen receptor (ER)–/progesterone receptor (PR)–/human epidermal growth
factor receptor-2 (HER2)–, Luminal A-like = ER+ and/or PR+ plus HER2–, Luminal B-like = ER+ and/or PR+ plus HER2+, HER2-enriched = ER–/ PR–/HER2+. CARE
Contraceptive and Reproductive Experiences Study, BCIS Breast Carcinoma in situ Study, LIFE Learning the Influence of Family and Environment Study
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response relationships were only observed in TNBC
(Ptrend = 0.01) and the luminal A-like subtype (Ptrend = 0.04)
among the African-American women. Among parous
African-American women, breastfeeding for 12 months or
longer compared to never breastfeeding was associated
with a 45% lower risk of TNBC (OR= 0.55, 95% CI = 0.32–
0.94), and 43% lower risk of luminal A-like breast cancer
(OR = 0.57, 95% CI = 0.36–0.90).
Table 2 Multivariable adjusted odds ratio (OR) and 95% confidence interval (CI) for ER/PR/HER2-defined subtypes of breast cancer
associated with reproductive factors
Controls Triple-negative Luminal A-like Luminal B-like HER2-enriched
N N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI)
All women
Age at menarche, years
≤ 12 1292 289 1.00 820 1.00 186 1.00 110 1.00
13 634 158 1.13 (0.90–1.41) 419 0.98 (0.84–1.16) 99 1.06 (0.81–1.40) 66 1.22 (0.88–1.69)
≥ 14 522 107 0.89 (0.69–1.14) 278 0.77 (0.64–0.92) 75 0.92 (0.68–1.24) 51 1.07 (0.75–1.53)
Trend P value 0.55 0.009 0.70 0.56
P value for homogeneity of trends 0.19
Number of completed pregnancies
Never pregnant 250 68 1.00 224 1.00 56 1.00 31 1.00
Any completed pregnancies 1990 431 0.91 (0.67–1.24) 1104 0.79 (0.64–0.98) 263 0.82 (0.58–1.15) 176 0.78 (0.50–1.20)
1 399 98 0.95 (0.66–1.36) 277 0.92 (0.71–1.19) 84 1.17 (0.79–1.74) 50 1.02 (0.62–1.67)
2 709 168 0.98 (0.70–1.37) 438 0.81 (0.64–1.02) 109 0.88 (0.61–1.29) 59 0.69 (0.42–1.11)
≥3 882 165 0.84 (0.60–1.19) 389 0.64 (0.50–0.81) 70 0.53 (0.35–0.80) 67 0.65 (0.40–1.05)
Trend P value 0.26 <0.0001 <0.0001 0.02
P value for homogeneity of trends 0.09
Only non-completed pregnancy 208 55 0.91 (0.60–1.38) 189 1.02 (0.76–1.35) 41 0.88 (0.55–1.39) 20 0.69 (0.38–1.26)
Parous women onlya,b
Age at first completed pregnancy, years
≤20 799 165 1.00 297 1.00 69 1.00 62 1.00
21–24 510 107 1.03 (0.78–1.38) 274 1.22 (0.98–1.52) 63 1.18 (0.80–1.73) 43 1.05 (0.68–1.62)
25–29 348 85 1.08 (0.77–1.52) 275 1.64 (1.28–2.10) 56 1.22 (0.78–1.89) 33 1.10 (0.66–1.85)
≥30 333 73 0.80 (0.54–1.20) 256 1.17 (0.88–1.55) 75 1.09 (0.68–1.74) 38 0.96 (0.55–1.70)
Trend P value 0.50 0.05 0.57 0.95
P value for homogeneity of trends 0.24
Duration of breastfeeding, months
Never 748 166 1.00 370 1.00 81 1.00 60 1.00
Ever 1242 264 0.80 (0.63–1.02) 732 0.78 (0.65–0.94) 182 0.89 (0.65–1.23) 116 0.91 (0.63–1.32)
< 6 541 134 0.96 (0.74–1.26) 303 0.83 (0.68–1.02) 82 0.99 (0.70–1.41) 35 0.68 (0.43–1.07)
6–11 263 40 0.55 (0.37–0.82) 165 0.76 (0.59–0.99) 35 0.70 (0.44–1.12) 33 1.28 (0.78–2.09)
≥ 12 438 90 0.69 (0.50–0.96) 264 0.71 (0.56–0.90) 65 0.85 (0.56–1.30) 48 1.10 (0.69–1.75)
Trend P value 0.006 0.004 0.28 0.36
P value for homogeneity of trends 0.08
Models in multivariate analysis included sub-study (the Women’s CARE Study or the Women’s BCIS Study, the Women’s LIFE Study), study site (Los Angeles,
Detroit), race (white, African-American), reference age (in 5-year age categories), education (≤ high school, technical school or some college, college graduate),
first-degree breast cancer family history (no, yes), body mass index (<25, 25–29, ≥30 kg/m2), a variable combining menopausal status and hormone therapy use
(premenopausal; postmenopausal: never used hormone therapy, ever used hormone therapy; unknown menopausal status), lifetime recreational physical activity
(inactive, ≤2.2, 2.3–6.6, 6.7–15.1, ≥15.2 annual metabolic equivalents of energy expenditure, hour/week), alcohol intake (never, former, current), cigarette smoking
status (never, former, current), age at menarche (≤12,13, ≥14 years), number of completed pregnancies (never pregnant, 1, 2, ≥3, only non-completed pregnancy),
oral contraceptive use (never, <1, 1–4, 5–9, ≥10 years). aModels additionally included age at first completed pregnancy (≤20, 21–24, 25–29, ≥30 years) and duration
of breastfeeding (never, <6, 6–11, ≥12 months). bAdditionally seven parous case participants who had missing information on breastfeeding were excluded.
Triple negative = estrogen receptor (ER)–/progesterone receptor (PR)–/human epidermal growth factor receptor-2 (HER2)–, Luminal A-like = ER+ and/or PR+ plus
HER2–, Luminal B-like = ER+ and/or PR+ plus HER2+, HER2-enriched = ER–/PR– /HER2 +
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The difference in trends across TNBC and luminal A-
like breast cancer was only statistically significant for age
at first completed pregnancy among parous white
women (P for homogeneity of trends = 0.02); none of the
other factors differed significantly between these two
subtypes (P for homogeneity of trends ≥0.10).
Table 3 Multivariable adjusted odds ratio (OR) and 95% confidence interval (CI) for ER/PR/HER2-defined subtypes of breast cancer
associated with reproductive factors by race
White women African-American women
Controls Triple-negative Luminal A-like Controls Triple-negative Luminal A-like
N N OR (95% CI) N OR (95% CI) N N OR (95% CI) N OR (95% CI)
All women
Age at menarche, years
≤12 793 167 1.00 631 1.00 499 122 1.00 189 1.00
13 433 102 1.12 (0.84–1.48) 327 0.90 (0.74–1.08) 201 56 1.09 (0.75–1.58) 92 1.18 (0.86–1.61)
≥14 323 74 0.99 (0.72–1.36) 220 0.78 (0.63–0.97) 199 33 0.69 (0.44–1.06) 58 0.75 (0.53–1.08)
Trend P value 0.89 0.02 0.16 0.26
P value for homogeneity of trends 0.10 0.68
Number of completed pregnancies
Never pregnant 199 56 1.00 200 1.00 51 12 1.00 24 1.00
Any completed pregnancies 1213 246 0.87 (0.61–1.24) 822 0.77 (0.61–0.97) 777 185 1.18 (0.59–2.36) 282 0.89 (0.51–1.54)
1 240 58 0.91 (0.59–1.40) 199 0.86 (0.65–1.16) 159 40 1.14 (0.54–2.43) 78 1.09 (0.60–1.97)
2 468 112 0.99 (0.67–1.45) 358 0.82 (0.63–1.06) 241 56 1.12 (0.54–2.35) 80 0.79 (0.44–1.42)
≥3 505 76 0.69 (0.45–1.05) 265 0.60 (0.45–0.79) 377 89 1.24 (0.60–2.57) 124 0.76 (0.43–1.36)
Trend P value 0.11 0.0005 0.62 0.13
P value for homogeneity of trends 0.48 0.12
Only non-completed pregnancy 137 41 1.02(0.63–1.64) 156 1.08 (0.78–1.49) 71 14 0.86 (0.35–2.08) 33 0.97 (0.49–1.90)
Parous women onlya,b
Age at first completed pregnancy, years
≤20 338 60 1.00 162 1.00 461 105 1.00 135 1.00
21–24 347 66 1.03 (0.68–1.56) 199 1.09 (0.82–1.44) 163 41 1.01 (0.65–1.58) 75 1.40 (0.96–2.04)
25–29 257 64 1.09 (0.69–1.70) 227 1.55 (1.14–2.10) 91 21 1.05 (0.59–1.89) 48 1.75 (1.10–2.80)
≥30 271 55 0.70 (0.42–1.17) 232 1.13 (0.80–1.60) 62 18 1.21 (0.61–2.41) 24 0.95 (0.51–1.77)
Trend P value 0.21 0.10 0.62 0.24
P value for homogeneity of trends 0.02 0.66
Duration of breastfeeding, months
Never 368 66 1.00 228 1.00 380 100 1.00 142 1.00
Ever 845 179 0.97 (0.68–1.38) 592 0.81 (0.64–1.02) 397 85 0.67 (0.47–0.96) 140 0.78 (0.57–1.06)
< 6 343 84 1.14 (0.78–1.68) 230 0.85 (0.66–1.10) 198 50 0.79 (0.52–1.19) 73 0.82 (0.57–1.18)
6–11 194 29 0.62 (0.37–1.05) 134 0.75 (0.54–1.02) 69 11 0.54 (0.26–1.09) 31 1.06 (0.63–1.77)
≥ 12 308 66 0.88 (0.56–1.39) 228 0.77 (0.57–1.04) 130 24 0.55 (0.32–0.94) 36 0.57 (0.36–0.90)
Trend P value 0.27 0.07 0.01 0.04
P value for homogeneity of trends 0.94 0.47
Triple negative = estrogen receptor (ER)–/progesterone receptor (PR)–/human epidermal growth factor receptor-2 (HER2)–, Luminal A-like = ER+ and/or PR+ plus
HER2. Models in multivariate analysis included sub-study (the Women’s CARE Study or the Women’s BCIS Study, the Women’s LIFE Study), study site (Los Angeles,
Detroit), reference age (in 5-year age categories), education (≤ high school, technical school or some college, college graduate), first-degree breast cancer family
history (no, yes), body mass index (<25, 25–29, ≥30 kg/m2), a variable combining menopausal status and hormone therapy use (premenopausal; postmenopausal:
never used hormone therapy, ever used hormone therapy; unknown menopausal status), lifetime recreational physical activity (inactive, ≤2.2, 2.3–6.6, 6.7–15.1, ≥15.2
annual metabolic equivalents of energy expenditure, hour/week), alcohol intake (never, former, current), cigarette smoking status (never, former, current), age at
menarche (≤12,13, ≥14 years), number of completed pregnancies (never pregnant, 1, 2, ≥3, only non-completed pregnancy), oral contraceptive use (never, <1, 1–4,
5–9, ≥10 years). aModels additionally included age at first completed pregnancy (≤20, 21–24, 25–29, ≥30 years) and duration of breastfeeding (never, <6, 6–11, ≥12 months).
bAdditionally, three white parous cases who had missing information on breastfeeding were excluded
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Reproductive factors and risk of TNBC and the luminal
A-like subtype by age
Similar to the results for all age groups combined, early
age at menarche, nulliparity, and older age at first com-
pleted pregnancy were not associated with risk of TNBC
in either younger or older women (Ptrend ≥0.13, Table 4).
However, younger women (aged 20–44 years) whose me-
narche occurred at age 14 years or later had a 37% lower
risk of luminal A-like breast cancer (OR = 0.63, 95% CI
= 0.47–0.85) than those whose menarche occurred at
age 12 years or earlier (Ptrend = 0.004). Number of com-
pleted pregnancies was inversely associated with the risk
of luminal A-like subtype cancer among both younger
(Ptrend = 0.02) and older women (Ptrend = 0.006). Among
older parous women, age at first completed pregnancy
was positively associated with the risk of the luminal A-
like subtype (Ptrend = 0.01); those who had their first
completed pregnancies at or after age 30 years had a
higher risk of the luminal A-like subtype than those who
had their first completed pregnancies at or prior to age
20 years (OR = 1.32, 95% CI = 0.91–1.90). Duration of
breastfeeding was inversely associated with the risk of
both TNBC and luminal A-like breast cancer subtypes in
both younger and older parous women.
The differences in trends across TNBC and luminal A-
like breast cancer were statistically significant only for
the number of completed pregnancies among younger
women (P for homogeneity of trends = 0.03).
Breastfeeding and risk of TNBC and luminal A-like breast
cancer by race and age
In our stratified analyses examining the association be-
tween breastfeeding and TNBC or luminal A-like breast
cancer by both race and age, we observed a stronger pro-
tective effect of longer duration of breastfeeding against the
risk of TNBC among younger parous African-American
women (Ptrend = 0.0004, Table 5); those who breastfed
for 6 months or longer had an 82% lower risk of TNBC
compared to their counterparts who had never breastfed
(OR = 0.18, 95% CI = 0.07–0.46). The other ORs for the
association between breastfeeding for 6 months or longer
and TNBC or the luminal A-like subtype were <1, but
their corresponding 95% CIs included the null value.
Additional results
The results for ER+/PR+/HER2– breast cancer, the
modified definition of the luminal A-like subtype recom-
mended by the 13th St. Gallen International Breast
Cancer Conference (2013) Expert Panel, were similar to
data presented in the tables for the more commonly used
definition (ER+ and/or PR+ plus HER2–) of the luminal
A-like breast cancer subtype. Moreover, when we ex-
cluded women diagnosed with in situ breast cancer, we
found that the results for TNBC were unchanged.
Discussion
In our pooled analysis of data from three population-
based case-control studies of women aged 20–64 years,
we found that longer duration of breastfeeding was asso-
ciated with decreased risk of both TNBC and the lu-
minal A-like subtype, especially for TNBC among
younger (20–44 years) parous African-American women.
Younger parous African-American women who breast-
fed for 6 months or longer had an 82% lower risk of
TNBC than their counterparts who had never breastfed.
If this is verified in future research, promotion of breast-
feeding, especially in younger African-American women
may have a particularly strong impact given the higher
risk of TNBC among African-American women [13–16].
Breastfeeding has been proposed to protect against
breast cancer through hormonal mechanisms that in-
clude postponing the resumption of ovulatory menstrual
cycles after a pregnancy [47], reducing estrogen levels in
the breast [48], and having fully differentiated breast tis-
sue that is less susceptible to the hormone milieu [49]. It
has also been proposed that breastfeeding has a direct
mechanical effect, by which carcinogenic agents are ex-
creted from the breast ductal tissue [50]. Moreover, as
the amount of involution of terminal duct lobular units
has been inversely associated with risk of breast cancer
[51], it has been hypothesized that long-term breastfeed-
ing could promote such involution, resulting in de-
creased risk of breast cancer, and particularly basal-like
breast cancers [52, 53]. The basal-like subtype is defined
according to cDNA microarray technology [54]. Because
cDNA microarray technology is not yet available clinic-
ally, TNBC has become a commonly used proxy for the
basal-like subtype in clinical and epidemiologic studies,
despite the fact that TNBC and the basal-like subtype
are discordant in 20–30% of cases [17, 55].
Our finding of a protective effect of a longer duration
of breastfeeding against the risk of TNBC agrees with
results from six previous case-control studies [6, 22, 23,
25, 27, 32], a pooled analysis of two case-control studies
[8], and one prospective study [21]. Moreover, three
case-control studies [15, 26, 28] and the African-American
Breast Cancer Epidemiology and Risk (AMBER) Consor-
tium [31] report a non-statistically significant protective ef-
fect of breastfeeding on TNBC (risk estimates for the
highest category of breastfeeding versus never breastfeeding
or lowest category = 0.70–0.91). No inverse association was
observed in one case-control study [24] and one prospect-
ive study [30]. A meta-analysis published in 2015 [56] con-
cluded that both case-control studies and cohort studies
support the evidence that ever breastfeeding is associated
with decreased risk of ER–/PR– breast cancer and of
TNBC. On average, ever breastfeeding was associated with
a 10% decrease in the risk of ER–/PR– breast cancer and
up to a 20% reduction in the risk of TNBC. A more recent
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meta-analysis published in 2016 [57] showed that ever
breastfeeding was associated with a 21% decrease in the risk
of TNBC (summary OR= 0.79, 95% CI = 0.66–0.94).
However, neither of these meta-analyses provided data on
the association between breastfeeding duration and risk of
TNBC.
Table 4 Multivariable adjusted odds ratio (OR) and 95% confidence interval (CI) for ER/PR/HER2-defined subtypes of breast cancer
associated with reproductive factors by age
Younger (20–44 years) Oldera (45–64 years)
Controls Triple-negative Luminal A-like Controls Triple-negative Luminal A-like
N N OR (95% CI) N OR (95% CI) N N OR (95% CI) N OR (95% CI)
All women
Age at menarche, years
≤12 491 139 1.00 299 1.00 801 150 1.00 521 1.00
13 252 94 1.35 (0.98–1.85) 152 0.94 (0.72–1.22) 382 64 0.90 (0.65–1.25) 267 0.94 (0.77–1.16)
≥14 227 58 0.86 (0.60–1.23) 98 0.63 (0.47–0.85) 295 49 0.85 (0.59–1.22) 180 0.85 (0.67–1.08)
Trend P value 0.72 0.004 0.33 0.18
P-value for homogeneity of trends 0.06 0.92
Number of completed pregnancies
Never pregnant 115 47 1.00 91 1.00 135 21 1.00 133 1.00
Any completed pregnancies 735 207 0.88 (0.58–1.32) 368 0.75 (0.54–1.05) 1255 224 1.06 (0.64–1.77) 736 0.82 (0.62–1.09)
1 193 48 0.75 (0.46–1.23) 107 0.83 (0.56–1.23) 206 50 1.30 (0.73–2.31) 170 1.01 (0.72–1.42)
2 289 83 0.94 (0.60–1.48) 159 0.82 (0.57–1.19) 420 85 1.15 (0.67–1.96) 279 0.80 (0.59–1.09)
≥ 3 253 76 0.98 (0.61–1.56) 102 0.59 (0.40–0.88) 629 89 0.85 (0.49–1.48) 287 0.70 (0.51–0.96)
Trend P value 0.73 0.02 0.13 0.006
P value for homogeneity of trends 0.03 0.83
Only non-completed pregnancy 120 37 0.91 (0.54–1.53) 90 1.03 (0.68–1.57) 88 18 1.08 (0.54–2.19) 99 1.10 (0.74–1.65)
Parous women onlyb,c
Age at first completed pregnancy, years
≤ 20 235 71 1.00 85 1.00 564 94 1.00 212 1.00
21–24 142 43 1.02 (0.63–1.65) 80 1.44 (0.95–2.17) 368 64 1.05 (0.72–1.54) 194 1.11 (0.85–1.44)
25–29 168 50 0.94 (0.57–1.56) 99 1.48 (0.97–2.27) 180 35 1.20 (0.74–1.94) 176 1.84 (1.34–2.51)
≥30 190 42 0.62 (0.34–1.12) 102 1.15 (0.71–1.86) 143 31 1.08 (0.61–1.89) 154 1.32 (0.91–1.90)
Trend P value 0.15 0.52 0.60 0.01
P value for homogeneity of trends 0.07 0.27
Duration of breastfeeding, months
Never 204 64 1.00 100 1.00 544 102 1.00 270 1.00
Ever 531 142 0.75 (0.50–1.12) 266 0.70 (0.50–0.99) 711 122 0.85 (0.62–1.17) 466 0.83 (0.67–1.03)
< 6 209 69 0.93 (0.60–1.44) 97 0.72 (0.49–1.05) 332 65 0.97 (0.67–1.39) 206 0.90 (0.70–1.16)
6–11 126 22 0.49 (0.27–0.89) 64 0.68 (0.44–1.07) 137 18 0.62 (0.35–1.10) 101 0.84 (0.60–1.17)
≥ 12 196 51 0.60 (0.35–1.01) 105 0.68 (0.44–1.05) 242 39 0.79 (0.50–1.24) 159 0.71 (0.53–0.96)
Trend P value 0.02 0.12 0.17 0.03
P value for homogeneity of trends 0.32 0.93
Triple-negative = estrogen receptor (ER)–/progesterone receptor (PR)–/human epidermal growth factor receptor-2 (HER2)–, Luminal A-like = ER+ and/or PR+ plus
HER2. Models in multivariate analysis included sub-study (the Women’s CARE Study or the Women’s BCIS Study, the Women’s LIFE Study), study site (Los Angeles,
Detroit), race (white, Africa-American), reference age (in 5-year age categories), education (≤ high school, technical school or some college, college graduate),
first-degree breast cancer family history (no, yes), body mass index (<25, 25–29, ≥30 kg/m2), lifetime recreational physical activity (inactive, ≤2.2, 2.3–6.6, 6.7–15.1,
≥15.2 annual metabolic energy equivalents, hour/week), alcohol intake (never, former, current), cigarette smoking status (never, former, current), age at menarche
(≤12,13, ≥14 years), number of completed pregnancies (never pregnant, 1, 2, ≥3, only non-completed pregnancy), oral contraceptive use (never, <1, 1–4, 5–9,
≥10 years). aAdditionally adjusted for a variable combining menopausal status and hormone therapy use (premenopausal; postmenopausal: never used hormone
therapy, ever used hormone therapy; unknown menopausal status). bModels additionally included age at first completed pregnancy (≤20, 21–24, 25–29, ≥30 years)
and duration of breastfeeding (never, <6, 6–11, ≥12 months). cAdditionally three younger case participants who had missing information on breastfeeding
were excluded
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Longer duration of breastfeeding was also associated
with decreased risk of the luminal A-like subtype in our
pooled analysis. Among previous studies that reported
results on the association between breastfeeding and the
luminal A-like subtype, breastfeeding was associated
with decreased risk of the luminal A-like subtype in
three case-control studies [6, 15, 22], but was not associ-
ated with risk of this subtype in three other studies [25,
27, 30]. The meta-analyses published in 2015 [56] and in
2016 [57] did not provide summary results specifically
for the luminal A-like subtype. However, the earlier pub-
lication [56] provided summary results for the ER+/PR+
subtype and concluded that the evidence for an inverse
association between ever breastfeeding and ER+/PR+
breast cancer was observed in case-control studies (sum-
mary OR = 0.86, 95% CI = 0.79–0.92), but not in cohort
studies (summary RR = 1.00, 95% CI = 0.90–1.10); the
later one [57] provided results for the luminal subtype
(ER+ and/or PR+) and showed that ever breastfeeding
was associated with a 23% decrease in risk of the luminal
subtype. In summary, the evidence for a protective effect
of breastfeeding against the risk of luminal A-like cancer
is not as strong as that for TNBC.
It has been well-documented that estrogen and pro-
gesterone play important roles in breast tumorigenesis
[58–60], and their effects on breast cells are mediated by
their respective receptors, the ER and the PR [61–64].
Furthermore, gene expression studies using cDNA
microarray technology show that the luminal-A subtype
is associated with ER signaling, whereas TNBC is
characterized by a basal-like molecular profile, typically
expressing genes involved in cell proliferation and differ-
entiation [54, 65]. In our pooled analysis, the fact that
early age at menarche, nulliparity, and late age at first
completed pregnancy were all associated with increased
risk of luminal A-like breast cancer, but not with TNBC,
provides additional evidence that these three reproduct-
ive factors affect breast cancer risk predominantly
through hormonal mechanisms.
Previous epidemiologic data on the impact of these
three factors on the risk of luminal A-like cancer and
TNBC are inconsistent, particularly for TNBC. Early age
Table 5 Multivariable adjusted odds ratio (OR) and 95% confidence interval (CI) for ER/PR/HER2-defined subtypes of breast cancer
associated with duration of breastfeeding among parous women by race and age
White women African-American women
Controls Triple-negative Luminal A-like Controls Triple-negative Luminal A-like
N N OR (95% CI) N OR (95% CI) N N OR (95% CI) N OR (95% CI)
Younger (20–44 years)a
Duration of breastfeeding, months
Never 85 27 1.00 57 1.00 119 37 1.00 43 1.00
Ever 383 105 0.85 (0.49–1.49) 218 0.71 (0.46–1.11) 148 37 0.43 (0.22–0.83) 48 0.58 (0.32–1.06)
<6 136 43 0.94 (0.52–1.72) 72 0.70 (0.43–1.14) 73 26 0.67 (0.33–1.36) 25 0.64 (0.32–1.26)
≥6 247 62 0.76 (0.41–1.41) 146 0.73 (0.45–1.18) 75 11 0.18 (0.07–0.46) 23 0.50 (0.24–1.06)
Trend P value 0.34 0.28 0.0004 0.07
P value for homogeneity of trends 0.93 0.09
Older (45–64 years)b
Duration of breastfeeding, months
Never 283 39 1.00 171 1.00 261 63 1.00 96 1.00
Ever 462 74 1.06 (0.65–1.72) 374 0.83 (0.63–1.10) 249 48 0.74 (0.47–1.17) 92 0.90 (0.62–1.30)
< 6 207 41 1.30 (0.78–2.19) 158 0.91 (0.67–1.25) 125 24 0.69 (0.39–1.21) 48 0.94 (0.60–1.46)
≥ 6 255 33 0.75 (0.41–1.38) 216 0.73 (0.53–1.02) 124 24 0.81 (0.46–1.43) 44 0.85 (0.54–1.35)
Trend P value 0.41 0.07 0.35 0.49
P value for homogeneity of trends 0.85 0.72
Triple negative = estrogen receptor (ER)–/progesterone receptor (PR)–/human epidermal growth factor receptor-2 (HER2)–, Luminal A-like = ER+ and/or PR+ plus
HER2. Models in multivariate analysis included sub-study (the Women’s CARE Study or Women’s BCIS Study, Women’s LIFE Study), study site (Los Angeles, Detroit),
reference age (in 5-year age categories), education (< high school, technical school or some college, college graduate), first-degree breast cancer family history
(no, yes), body mass index (<25, 25–29, ≥30 kg/m2), lifetime recreational physical activity (inactive, ≤2.2, 2.3–6.6, 6.7–15.1, ≥15.2 annual metabolic energy equivalents,
hour/week), alcohol intake (never, former, current), cigarette smoking status (never, former, current), age at menarche (≤12,13, ≥14 years), number of completed
pregnancies (1, 2, ≥3), oral contraceptive use (never, <1, 1–4, 5–9, ≥10 years) and age at first completed pregnancy (≤20, 21–24, 25–29, ≥30 years). aAdditionally three
white younger case participants who had missing information on breastfeeding were excluded. bAdditionally adjusted for a variable combining menopausal status and
hormone therapy use (premenopausal; postmenopausal: never used hormone therapy, ever used hormone therapy;
unknown menopausal status)
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at menarche was not associated with risk of TNBC in
three case-control studies [22, 23, 27], three prospective
studies [20, 21, 30], and one pooled analysis of 34 studies
[9]; however, it was a risk factor for TNBC in several
other studies [10, 15, 24–26, 29]. Some studies found no
association between nulliparity and risk of TNBC [6, 9,
10, 26, 27, 30, 57], whereas another reported an in-
creased risk of TNBC associated with nulliparity [23].
Others showed a reduced risk of TNBC with nulliparity
[20, 25, 28, 31, 32]. Some studies found no association of
risk of TNBC with late age at first full-term pregnancy
[6, 10, 20] or first birth [21, 26, 27, 29, 30, 57]; one study
showed an increased risk of TNBC associated with late
age at first birth [24] whereas others showed a reduced
risk of TNBC associated with increasing age at first
birth [9, 25]. Our findings are consistent with the ma-
jority of previous analyses of early age at menarche
[9, 20–23, 27, 30], nulliparity [6, 9, 10, 26, 27, 30,
57], and late age at first full-term pregnancy [6, 10,
20] or first birth [21, 26, 27, 29, 30, 57], showing that
these three reproductive factors were not associated
with the risk of TNBC.
African-American women are more likely than white
women to be diagnosed with TNBC, especially at a
young age (<45 years) [13–16]. In the high risk group,
we observed an inverse association between breastfeed-
ing and risk of TNBC, suggesting that the protective ef-
fect of breastfeeding against risk of TNBC is modified by
age and race. To our knowledge, no data have previously
been published on effect modification by age for the as-
sociation between breastfeeding and risk of TNBC. The
observed reductions in risk of breast cancer overall in
many previously published studies have been stronger
for or restricted to younger or premenopausal women
[66–71]; however, in some studies, this reduction in risk
of breast cancer risk was observed among postmeno-
pausal women [72–74] or was negligible in both pre-
menopausal and postmenopausal women [75, 76]. Two
studies found that the protective effect of breastfeeding
against breast cancer decreased with the increasing time
since last pregnancy [66, 77]. The reduction in risk of
TNBC associated with breastfeeding was stronger for
younger than for older African-American women, which
was similar to the results for breast cancer overall.
Moreover, there are few data on whether race modifies
the association between breastfeeding and TNBC. The
study of Work et al. provides some evidence of effect
modification: multiparous women (≥3 live births) who
never breastfed were at increased risk of ER–/PR– breast
cancer, whereas multiparous women with a history of
breastfeeding were at decreased risk of ER–/PR– breast
cancer [32]. These associations were more apparent
in African-American women than in non-Hispanic
white women. Using data from the AMBER Consortium,
Palmer et al. found that breastfeeding ameliorated the in-
creased risk of TNBC associated with multiparity [31].
Our data also provide some evidence that breastfeed-
ing may be important for limiting the increased risk of
TNBC among parous African-American women, but not
among parous white women (data not shown). The ob-
served racial difference in our results for the inverse as-
sociation between breastfeeding and risk of TNBC could
not be explained by breastfeeding duration; African-
American controls and case participants with TNBC had
a shorter duration of breastfeeding on average than did
white controls and case participants with TNBC (mean
breastfeeding duration among those who ever had
breastfed: 10.8 and 10.2 months for African-American
controls and TNBC case participants, respectively; 12.7
and 13.1 months among white controls and TNBC case
participants, respectively). The observed difference in
breastfeeding results between African-American women
and white women could be related to the differences in
other characteristics, such as genetic susceptibility, and
requires further study.
Strengths of this pooled analysis include its size, espe-
cially the large number of case participants with incident
TNBC. Furthermore, the data used in this analysis were
collected by trained interviewers, who administered
standardized, in-person interviews using structured
questionnaires, which were nearly identical across three
source studies.
Several limitations of the current study must be con-
sidered. First, approximately 36% of our case participants
had missing data on at least one of the receptors (ER,
PR, or HER2). We compared our measures of reproduct-
ive factors in case patients with and without known ER,
PR, or HER2. No statistically significant differences were
detected for age at menarche, number of completed
pregnancies, or duration of breastfeeding, whereas case
patients with information on ER/PR/HER2 were 0.9 years
older on average at first completed pregnancy than those
with missing information on ER, PR, or HER2 (data not
shown). The small difference in average age at first com-
pleted pregnancy is unlikely to have altered the observed
associations differentially by tumor subtypes.
Second, ER/PR/HER2 status in two of our source studies
[6, 35] was assayed at the same laboratory using the same
methods, whereas in the third source study [33] the infor-
mation on ER/PR/HER2 status was abstracted from med-
ical records collected by the LACSP. Our previous
validation study showed that the associations between re-
productive factors and risk of the ER/PR subtypes of breast
cancer were similar, whether the ER/PR values were from
the same centralized laboratory at the USC providing as-
says for this analysis or from the LACSP [44]. In addition,
we repeated our analyses with the two of our source stud-
ies with ER/PR/HER2 values from the centralized USC
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laboratory and found that the results were similar (data not
shown) to those presented here.
A final limitation is that IHC was used to assess HER2
protein overexpression without validation by fluorescent
in situ hybridization (FISH) analysis in the Women’s
CARE Study and the Women’s BCIS Study. Based on
previous validation results from the same centralized USC
pathology laboratory, 7.4% of breast tumors with HER2
gene amplification in FISH analysis were false negative by
10H8-IHC (scored as 0 or 1+) and 9.7% of breast cancers
without HER2 gene amplification in FISH analysis were
false positive [42]. These misclassifications could cause
bias towards the null for testing heterogeneity across
subtypes involving HER2– versus HER2+ tumors,
such as TNBC versus HER2-enriched cancer.
Conclusions
In this pooled analysis, longer duration of breastfeeding
was associated with decreased risk of TNBC especially
in younger parous African-American women, suggesting
a potential role of breastfeeding in prevention of TNBC
among these women.
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